Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers February 19, 2018
Pharmacy Choice - News - Pharmaceutical Development - February 19, 2018

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

2/19/18 - "Methods of Detecting Cancer" in Patent Application Approval Process (USPTO 20180030145)
By a News Reporter-Staff News Editor at Cancer Vaccine Week A patent application by the inventors Soler, David C.; Sloan, Andrew E.; Cooper, Kevin D.; McCormick, Thomas S.; Young, Andrew B., filed on July 28, 2017, was made available online on February 8, 2018, according to news reporting originating from Washington, D.C., by NewsRx correspondent
2/19/18 - "Panobinostat Dosages for Multiple Myeloma" in Patent Application Approval Process (USPTO 20180028497)
By a News Reporter-Staff News Editor at Pharma Business Week A patent application by the inventors Lin, Rong; Capdeville, Renaud; Grazioli, Laura; Mu, Song; Paul, Sofia; Binlich, Florence, filed on February 17, 2016, was made available online on February 8, 2018, according to news reporting originating from Washington, D.C., by NewsRx corresponde
2/19/18 - 60 Pharmaceuticals 60P Receives Priority Review Designation For Malaria Drug
By a News Reporter-Staff News Editor at Pharma Business Week 60 Degrees Pharmaceuticals received Priority Review Designation from the United States Food and Drug Administration for Tafenoquine for prevention of malaria in adults. The FDA informed 60 P of this designation upon filing of its' New Drug Application. TQ has the advantage of a convenie
2/19/18 - Abide Therapeutics to Participate in February 2018 Investor Conferences
By a News Reporter-Staff News Editor at Clinical Trials Week Abide Therapeutics, a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting the serine hydrolase family of enzymes, announced that Alan Ezekowitz, CEO and President, will present an overview of the company at the 20th Annual BIO CEO& Investor Confer
2/19/18 - Appili Therapeutics Raises an Additional $4.3 Million in Oversubscribed Financing to Advance its Anti-infective Pipeline
By a News Reporter-Staff News Editor at Pharma Business Week Appili Therapeutics Inc., a biopharmaceutical company developing and commercializing anti-infective drugs, announced it raised an additional $4,339,000 in an oversubscribed private placement financing, bringing the total equity raised since its seed round in March 2016 to $11,816,000.
2/19/18 - AstraZeneca's IMFINZI approved for Stage III nsclc
AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration has approved Imfinzi for the treatment of patients with unresectable Stage III non-small cell lung cancer whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
2/19/18 - AstraZeneca: Imfinzi Receives FDA Approval To Treat Unresectable Stage III NSCLC
LONDON- AstraZeneca PLC and MedImmune announced the. US FDA has approved Imfinzi for the treatment of patients with unresectable Stage III non-small cell lung cancer whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. The approval is based on the positive PFS data from the Phase III PACIFIC trial
2/19/18 - BerGenBio completes recruitment into first stage of Phase II breast cancer trial with selective AXL inhibitor bemcentinib combined with KEYTRUDA
Bergen, Norway, 19 February 2018- BerGenBio ASA announces that it has completed enrolment, ahead of schedule, of the planned 28 patients into the first stage of its Phase II clinical trial evaluating its investigational oral selective AXL inhibitor bemcentinib in combination with the Merck& Co., Inc., Kenilworth, N.J., USA anti-PD-1 therapy KEYTRUD
2/19/18 - BerGenBio Completes Recruitment Into First Stage of Phase II Breast Cancer Trial With Selective AXL Inhibitor Bemcentinib Combined With KEYTRUDA
BerGenBio ASA announces that it has completed enrolment, ahead of schedule, of the planned 28 patients into the first stage of its Phase II clinical trial evaluating its investigational oral selective AXL inhibitor bemcentinib in combination with the Merck& Co., Inc., Kenilworth, N.J., USA anti-PD-1 therapy KEYTRUDA as a potential new treatmen
2/19/18 - Black patients more likely to be excluded from prostate cancer trials
By a News Reporter-Staff News Editor at Clinical Trials Week Boston, MA Clinical trials can offer patients access to cutting-edge treatments with the potential to extend their survival and shape the standard of care in the future. A team of investigators from Brigham and Women's Hospital studied a potential barrier that may be disproportionatel
2/19/18 - bluebird bio to Present at LEERINK Partners Global Healthcare Conference
By a News Reporter-Staff News Editor at Cancer Gene Therapy Week bluebird bio, Inc., a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced that members of the management team will present at the LEERINK Partners 7th Annual Globa
2/19/18 - Bonti Announces Dosing of the First Patient in the SHINE-1 Phase 2 Clinical Study Evaluating EB-001 for Scar Reduction
By a News Reporter-Staff News Editor at Pharma Business Week Bonti, a privately-held, clinical-stage biotechnology company, announced the initiation of the SHINE clinical program, aimed at scar reduction using its novel neurotoxin. Considering the potential advantages of this profile, Bonti continues developing products to pursue targeted aesthet
2/19/18 - Breathing problems linked to drug that treats opioid addiction
By a News Reporter-Staff News Editor at Pharma Business Week A drug used to treat opioid addiction could cause breathing problems in some obese patients, according to a new study from UT scientists. It is one of three drugs approved by the US Food and Drug Administration to help patients undergoing treatment for opioid abuse. The discovery of the
2/19/18 - Cell Culture Market Analysis Focusing On Major Companies (ABB Ltd., General Electric Company, Eaton, Siemens AG), Research Methodology, and Forecast By 2024
Cell Culture Market By Product, Application, Process, End-User, Geography- Industry Trends, Trends, Size, Share and Forecast to 2024. The Global Cell Culture Market accounted to USD 12,585.9 million in 2016 growing at a CAGR of 10.0% during the forecast period of 2017 to 2024. *Higher Prices of Cell Biology Research.
2/19/18 - Churchill Pharmaceuticals Announces YONSATM Clinical Data to be presented at ASCO GU in San Francisco
By a News Reporter-Staff News Editor at Clinical Oncology Week Churchill Pharmaceuticals LLC announced that positive data from the STAAR and STAAR-E clinical trials, evaluating YONSA? for the treatment of men with metastatic castration-resistant prostate cancer, will be presented at the 2018 American Society of Clinical Oncology, Genitourinary.
2/19/18 - Clene Nanomedicine Announces Preclinical Results of A Novel Gold Nanocrystal Remyelinating Treatment for Multiple Sclerosis at ACTRIMS Forum Annual...
Clene Nanomedicine Announces Preclinical Results of A Novel Gold Nanocrystal Remyelinating Treatment for Multiple Sclerosis at ACTRIMS Forum Annual Meeting. By a News Reporter-Staff News Editor at Pharma Business Week Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company developing a new class of Clean Surface Nanotherapeutic drugs
2/19/18 - Contract Research Organization Services (CROS) Market share analysis of the top industry players includes IQVIA, LabCorp, PAREXEL, Syneos Health and Investment Opportunities for next 5 years
Stay up-to-date with global Contract Research Organization Services market research offered by HTF MI. The study is segmented by Application/ end users, products type and various important geographies like United States, EU, Japan, China, India& Southeast Asia]. The study provides company profiling, product picture and specifications, sales, market
2/19/18 - Daiichi Sankyo Initiates Phase 1 Study of U3-1402 in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
By a News Reporter-Staff News Editor at Pharma Business Week Daiichi Sankyo Company, Limited announced that the first patient has been dosed in a phase 1 study evaluating the safety and tolerability of U3-1402, an investigational and potential first-in-class HER3-targeting antibody drug conjugate, in patients with metastatic or unresectable epide
2/19/18 - Data on Cellulitis Discussed by Researchers at Department of Surgery (Clinical characteristics affecting length of stay in patients with cellulitis)
According to news originating from Auckland, New Zealand, by NewsRx correspondents, research stated, "This study aimed to profile the clinical characteristics of patients presenting to Middlemore Hospital with cellulitis in order to identify factors that are associated with an increased length of stay. For more information on this research see: Cli
2/19/18 - Data on Clinical Trials and Studies Detailed by Researchers at Copenhagen University Hospital (Physical performance following acute high-risk...
Data on Clinical Trials and Studies Detailed by Researchers at Copenhagen University Hospital. According to news originating from Hvidovre, Denmark, by NewsRx correspondents, research stated, "Acute high-risk abdominal surgery is associated with high mortality, multiple postoperative complications and prolonged hospital stay. Our news journalists..
2/19/18 - Elekta's Leksell Gamma Knife Icon Radiosurgery System Cleared for use in China
By a News Reporter-Staff News Editor at Pharma Business Week Elekta's Leksell Gamma Knife Icon? radiosurgery system has received clearance from the China Food and Drug Administration, enabling health care providers in the country to offer this advanced technology to their patients. In China, more than 100,000 people are diagnosed each year w
2/19/18 - Embrace by Empatica is the world's first smart watch to be cleared by FDA for use in Neurology
By a News Reporter-Staff News Editor at Clinical Trials Week Empatica Inc has received clearance from the FDA for Embrace, its award-winning smart watch. Embrace uses AI to monitor for the most dangerous kinds of seizures, known as "grand mal" or "generalized tonic-clonic" seizures, and send an alert to summon caregivers' help. In a multi-site cl
2/19/18 - Endo Announces Initiation Of Two Pivotal Phase 3 Clinical Trials Of Collagenase Clostridium Histolyticum For The Treatment Of Cellulite
By a News Reporter-Staff News Editor at Pharma Business Week Endo International plc announced the initiation of two identical Phase 3 RELEASE* clinical trials of collagenase clostridium histolyticum for the treatment of cellulite. "Despite the number of options currently marketed as cellulite remedies, there still are no U.S. Food and Drug Admin
2/19/18 - Eribulin Mesylate Nearly Doubles Overall Survival in Previously Treated Patients with Advanced Liposarcoma in Subanalysis Published in the Journal of...
Eribulin Mesylate Nearly Doubles Overall Survival in Previously Treated Patients with Advanced Liposarcoma in Subanalysis Published in the Journal of Clinical Oncology. By a News Reporter-Staff News Editor at Clinical Trials Week Eisai Inc. announced the publication of results from a subgroup analysis of the pivotal Phase 3 study comparing eribul
2/19/18 - ERLEADA? apalutamide, a Next-Generation Androgen Receptor Inhibitor, Lowered Risk of Metastasis or Death in Patients with Non-Metastatic...
By a News Reporter-Staff News Editor at Clinical Trials Week The Janssen Pharmaceutical Companies of Johnson& Johnson announced new findings from the Phase 3 SPARTAN clinical trial that showed treatment with ERLEADA?, an investigational, next-generation1 androgen receptor inhibitor, decreased risk of metastasis or death by 72 percent and improv
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2018 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415